Cargando…

The MEK1/2 Pathway as a Therapeutic Target in High-Grade Serous Ovarian Carcinoma

SIMPLE SUMMARY: High-grade serous ovarian carcinoma (HGSOC) has poor prognosis for patients due to its high rate of recurrence and acquired resistance to therapy. MEK1/2-ERK1/2 signaling pathway that controls cell proliferation and survival is active in the majority of HGSOC cases, but its functiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chesnokov, Mikhail S., Khan, Imran, Park, Yeonjung, Ezell, Jessica, Mehta, Geeta, Yousif, Abdelrahman, Hong, Linda J., Buckanovich, Ronald J., Takahashi, Akimasa, Chefetz, Ilana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003094/ https://www.ncbi.nlm.nih.gov/pubmed/33803586 http://dx.doi.org/10.3390/cancers13061369

Ejemplares similares

Optimized Transcriptional Signature for Evaluation of MEK/ERK Pathway Baseline Activity and Long-Term Modulations in Ovarian Cancer
por: Chesnokov, Mikhail S., et al.
Publicado: (2022)

How to win the ovarian cancer stem cell battle: destroying the roots
por: Takahashi, Akimasa, et al.
Publicado: (2020)

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
por: Iyengar, Mangala, et al.
Publicado: (2018)

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition
por: Llaurado Fernandez, Marta, et al.
Publicado: (2022)

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment
por: Han, Chanhee, et al.
Publicado: (2018)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
por: Tholander, Bengt, et al.
Publicado: (2020)

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
por: Fernandez, Marta Llaurado, et al.
Publicado: (2019)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib
por: Takekuma, Munetaka, et al.
Publicado: (2016)

Carcinoma-Associated Mesenchymal Stem Cells Promote Chemoresistance in Ovarian Cancer Stem Cells via PDGF Signaling
por: Raghavan, Shreya, et al.
Publicado: (2020)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

The Genomic Landscape of Centromeres in Cancers
por: Saha, Anjan K., et al.
Publicado: (2019)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas
por: Gruosso, Tina, et al.
Publicado: (2015)

Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient
por: Colombo, Ilaria, et al.
Publicado: (2019)

Response to re-challenge of a MEK inhibitor in a patient with recurrent low-grade serous carcinoma of the peritoneum
por: Gershenson, David M., et al.
Publicado: (2020)

Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
por: Newtson, Andreea, et al.
Publicado: (2021)

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma
por: Norris, Eric J, et al.
Publicado: (2019)

Prognostic gene expression signature for high-grade serous ovarian cancer
por: Millstein, J., et al.
Publicado: (2020)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

NUAK Kinases: Brain–Ovary Axis
por: Molina, Ester, et al.
Publicado: (2021)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

Trends of low-grade serous ovarian carcinoma in the United States
por: Matsuo, Koji, et al.
Publicado: (2018)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma
por: Stur, Elaine, et al.
Publicado: (2022)

Principles of dormancy evident in high-grade serous ovarian cancer
por: Shepherd, Trevor G., et al.
Publicado: (2022)

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers
por: Azzalini, Eros, et al.
Publicado: (2023)

First-Line Management of Advanced High-Grade Serous Ovarian Cancer
por: Mahmood, Reem D., et al.
Publicado: (2020)

BMPs morph into new roles in ovarian cancer
por: McLean, Karen, et al.
Publicado: (2013)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
por: Chowdhury, Shrabanti, et al.
Publicado: (2023)

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Ducie, Jennifer, et al.
Publicado: (2017)

Fallopian tube secreted protein affects ovarian metabolites in high grade serous ovarian cancer
por: Bergsten, Tova M., et al.
Publicado: (2022)

Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics
por: Gross, Amy L., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_fcgrf1jq29bks5634o9sf8d40e